MENLO PARK, Calif., April 30, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), today announced the closing of a $21.5 million Series A financing round led by Ajax Health. Ablacon’s novel algorithm uses artificial intelligence (AI) to analyze and visualize […]
Financial
AtriCure Reports First Quarter 2019 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2019 financial results. “We had a good start to the year fueled by solid performance across our business in the first quarter,” said Mike Carrel, President […]
Endonovo Therapeutics Provides Corporate Update
LOS ANGELES, CA, April 26, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announced a corporate update and business plan for the remainder of 2019. Revenue projections for the first quarter ended March 31, 2019 are expected to […]
Zynex Schedules 2019 First Quarter Earnings
ENGLEWOOD, Colo., April 25, 2019 /PRNewswire/ — Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announces today that it will host the Company’s 2019 first quarter investor webcast on Tuesday, April 30, 2019 at 2:15 p.m. Mountain […]
NeoChord Raises Additional Financing to Drive Catheter-based Program Development, Bringing Total Series D Funding to over $32 Million
ST. LOUIS PARK, Minn., April 23, 2019 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced today that it has secured additional funding as an extension of its Series D equity financing, which […]
Boston Scientific Announces Results For First Quarter 2019
MARLBOROUGH, Mass., April 24, 2019 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an operational1 basis and 6.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP […]
Merit Medical Reports Earnings for Quarter Ended March 31, 2019
SOUTH JORDAN, Utah, April 23, 2019 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced revenue of $238.3 million for the quarter ended […]
Rapid Medical Raises $20 Million in New Funding to Support Clinical and Commercialization of First-in-class Stroke Treatment Products
YOKNEAM, Israel, April 23, 2019 /PRNewswire/ — Rapid Medical, a company focused on the development of interventional neurovascular devices, announced today that it has completed an oversubscribed Series C financing of $20 million. The proceeds will be used for the completion of the TIGER U.S. IDE study and to support accelerating commercial growth […]
Cerenis Therapeutics has Decided to Terminate the Proposed Merger with H4Orphan Pharma
TOULOUSE, France–(BUSINESS WIRE)–Regulatory News: Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, announces that the […]
ABBOTT REPORTS FIRST-QUARTER 2019 RESULTS
ABBOTT PARK, Ill., April 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2019. First-quarter worldwide sales of $7.5 billion increased 2.0 percent on a reported basis and 7.1 percent on an organic* basis. Reported diluted EPS from continuing operations under GAAP was $0.38 in the first quarter. […]



